Analyst Ratings January 27, 2026

TD Cowen Raises RTX Price Target to $225 After Strong Q4; Maintains Buy Rating

Research firm cites conservative 2026 guidance for Pratt & Whitney and Raytheon and anticipates upward estimate revisions

By Maya Rios RTX
TD Cowen Raises RTX Price Target to $225 After Strong Q4; Maintains Buy Rating
RTX

TD Cowen increased its price objective on RTX Corp. to $225 from $210 while keeping a Buy rating, following what the firm described as strong fourth-quarter results. The new target implies a 25 times EV/EBITDA multiple on RTX’s estimated calendar year 2026 results. The stock, trading near its 52-week high, posted quarterly earnings and revenue above expectations.

Key Points

  • TD Cowen raised RTX’s price target to $225 from $210 and kept a Buy rating after strong fourth-quarter results.
  • The $225 target implies 25 times estimated calendar year 2026 EV/EBITDA; RTX currently trades at EV/EBITDA of 21.01 and a P/E of 41.36.
  • Sectors impacted include aerospace and defense, with market and investor sentiment affected by earnings beats and guidance expectations.

Overview

TD Cowen has lifted its price target for RTX Corp. to $225.00 from $210.00 and retained a Buy rating on the shares. The research firm's adjustment follows what it characterized as strong fourth-quarter results from the aerospace and defense company.

Share performance and valuation

RTX is trading at $201.28, roughly 0.99% below its 52-week high of $203.03, after delivering a 58.14% price return over the past year. According to InvestingPro data cited in the research discussion, the stock appears overvalued when compared with its Fair Value estimate.

Rationale for the price-target increase

TD Cowen pointed to multiple factors behind the higher $225 target. The firm said RTX’s initial guidance for calendar year 2026 looks conservative, particularly for the company’s Pratt & Whitney and Raytheon business segments, and expects that guidance and consensus estimates will be revised upward over the course of the year, according to the analyst note.

The new $225 target corresponds to a valuation of 25 times RTX’s estimated calendar year 2026 EV/EBITDA. By comparison, the company currently trades at an EV/EBITDA multiple of 21.01 and a price-to-earnings ratio of 41.36. InvestingPro identifies RTX as "trading at a high EBITDA valuation multiple."

Analyst views and consensus

Analyst price targets for RTX currently span a range from $150 to $230. InvestingPro also lists 13 additional investment insights about the company and highlights a comprehensive Pro Research Report covering RTX among its analysis of more than 1,400 U.S. stocks.

Recent quarterly results

RTX reported fourth-quarter 2025 results that exceeded analysts' expectations. The company posted earnings per share of $1.55 versus a forecast of $1.47, and revenue of $24.2 billion compared with an anticipated $22.69 billion. The earnings release was followed by an increase in RTX shares during pre-market trading.

Market reaction and analyst activity

Despite the strong quarterly numbers and TD Cowen's raised target, no analyst upgrades or downgrades were reported in direct connection with the earnings release.


Conclusion

TD Cowen's adjusted target and maintained Buy rating reflect confidence in RTX's near-term performance and potential upside in 2026 results, while third-party valuation data flag a higher-than-average EBITDA multiple relative to the company's Fair Value estimate.

Risks

  • InvestingPro data indicates RTX appears overvalued relative to its Fair Value estimate, reflecting valuation risk for investors in the stock.
  • RTX is described as trading at a high EBITDA valuation multiple, which could present downside if expected upward revisions to 2026 guidance do not materialize.
  • Analyst price targets vary from $150 to $230, indicating a range of opinions that underscores uncertainty in consensus valuation.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026